Procox Oral Suspension – 7.5 ml

Name:
· Procox Oral Suspension – 7.5 ml

Manufacturer:
· Vetoquinol

Description:
· Recommended for dogs in case of suspected or demonstrated mixed parasitic infestations caused by roundworms and coccidia.

Ingredients:
· Emodepsid 0.9 mg
· Toltrazuril 18 mg
· Excipients: Butylhydroxytoluene (E321; as an antioxidant) 0.9 mg, Sorbic acid (E200; preservative) 0.7 mg, Sunflower oil Glycerol dibehenate

Key benefits:
Procox is effective in the case of mixed parasitic infestations caused by roundworms and coccidia of the following species:
Ø Roundworms (Nematode):
– Toxocara canis (mature adult, immature adult, L4)
– Uncinaria stenocephala (mature adult)
– Ancylostoma caninum (mature adult) – Trichuris vulpis (mature adult)
Ø Coccidia:
– Isospora ohioensis complex
– Isospora canis

· Procox is effective against Isospore multiplication and against oocyst dispersion. Although the treatment reduces the spread of the infestation, it will not be effective in already infested animals that show clinical signs.

Intended for:
· Dogs.

Method of administration:
· Oral.
· Shake before use.
· Unscrew the cover.
· Use a standard disposable syringe with a Luer tip for each treatment.
· To ensure accurate dosing, for dogs weighing up to 4 kg, use a graduated syringe with 0.1 ml graduations.
· For dogs weighing more than 4 kg, use a graduated syringe with 0.5 ml graduations.
· Push the tip of the syringe firmly into the opening of the vial.
· Then, turn the vial over and withdraw the required volume of suspension.
· Turn the vial back into an upright position before removing the syringe.
· After use, screw on the cover.
· Administer the suspension into your dog‘s mouth.

Form of presentation:
· 7.5 ml bottle.

Dosage:
· For oral use in dogs from 2 weeks of age and weighing at least 0.4 kg.
· The minimum recommended dose is 0.5 ml/kg body weight, equivalent to 0.45 mg emodepsid/kg body weight and 9 mg toltrazuril/kg body weight.
· The recommended doses are specified in the second picture.

Precautions:
· Do not use in dogs/puppies under 2 weeks of age or weighing less than 0.4 kg.
· Procox is effective against coccidia multiplication and oocyst dispersal. The multiplication of parasites damages the intestinal mucosa of dogs, can cause enteritis. Therefore, treatment with Procox does not lead to the disappearance of clinical symptoms caused by mucosal damage (e.g. diarrhoea) that appeared before treatment. In these cases, supportive treatment is required.
· The treatment against Isospora aims to minimize the release of oocysts into the environment and thus reduces the risk of infestation in the case of groups/kennels that have a history of recurrent infestations with Isospora. A prevention strategy, including efforts to eliminate the infestation, must be initiated. Treatment with Procox is one of the necessary measures in this strategy.

· It is important that hygiene measures are applied, especially the environment, to be as dry and clean as possible in order to reduce the risk of re–infestations in the environment.
· Isospore oocysts are resistant to many disinfectants and can survive in the environment for long periods of time.
· Rapid elimination of feces, before oocyst sporulation, (within 12 hours) reduces the risk of transmission of the infestation.
· A single administration of Procox to the nest/group is generally sufficient to reduce the dispersal of Isospora oocysts within it. In kennels with repeated infestations and clinical signs caused by Isospora infestation, each nest must be treated for a long period of time to combat and gradually reduce the level of infestation.
· All dogs in the group that are at risk of infestation should be treated at the same time, including adult animals as they can be infested subclinically.
· Diagnostic methods (faecal flotation) may be useful to determine the presence and number of oocysts dispersed within groups of animals at the end of a control programme in order to monitor its success.
· Procox is not recommended for use in Collie or related breeds that are known or suspected to have the mdr1 mutation, as the tolerance to the product of mdr1 mutant puppies has been shown to be lower than in other puppies. Emodepside is a substrate for P–glycoprotein.
· There is limited experience with the use of the product in weak dogs or dogs with renal and hepatic impairment. Therefore, the veterinary medicinal product may be used in these animals only with the consent of the responsible veterinarian, after a benefit/risk assessment.
· The safety of the veterinary medicinal product has not been established during gestation and lactation in dogs.
· Use in pregnant and in during the first two weeks of lactation is therefore not recommended.

How to store:
· Store in a place away from moisture and direct exposure to the sun, at temperatures up to 25°C.

In case of overdose:
· The safety of the recommended dose has been demonstrated in puppies treated every two weeks up to five times.
· Occasionally, weak and transient dysfunction of the digestive tract such as vomiting or diarrhoea may occur when the veterinary medicinal product has been repeatedly administered at doses up to 5 times the recommended dose.
· In case of overdose, please contact your veterinarian urgently.